Key result
Receipt of ACEIs or ARBs was associated with a significantly lower risk of mortality (aOR 0.57; 95% CI 0.43-0.76; P<.001) and severe adverse events among patients with COVID-19.
Why the study?
Chronic receipt of ACEIs and ARBs was assumed to exacerbate complications and produce worse clinical outcomes in patients with COVID-19.
Does the receipt of ACEIs or ARBs reduce mortality and severe adverse events in adult patients with COVID-19?
Population
101 949 adult patients with COVID-19 across 52 studies
Comparison
Receipt vs nonreceipt of ACEIs or ARBs
Design
Systematic review and meta-analysis
Authors
Loading...
Supports continuing ACEI/ARB therapy in COVID-19; reinforces safety and extends evidence of possible benefit.
Meta-Analysis (n=101,949)
Does the receipt of ACEIs or ARBs reduce mortality and severe adverse events in adult patients with COVID-19?
Odds Ratio: 0.57 (95% CI 0.43–0.76)
p-value: p=<.001
In patients with COVID-19, continuing ACEIs or ARBs is safe and may be associated with a reduced risk of mortality and severe adverse events, particularly among patients with hypertension.
Baral et al. (2021) conducted a meta-analysis in COVID-19 (n=101,949). ACEIs or ARBs vs. nonreceipt of ACEIs or ARBs was evaluated on mortality (aOR 0.57, 95% CI 0.43-0.76, p=<.001). Receipt of ACEIs or ARBs was associated with a significantly lower risk of mortality (aOR 0.57; 95% CI 0.43-0.76; P<.001) and severe adverse events among patients with COVID-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: